TIA
MCID: TRN015
MIFTS: 58

Transient Cerebral Ischemia (TIA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Transient Cerebral Ischemia

MalaCards integrated aliases for Transient Cerebral Ischemia:

Name: Transient Cerebral Ischemia 12 55 15 73
Transient Ischemic Attack 12 54 55 6 43 15 73
Tia - Transient Ischaemic Attack 12
Transient Cerebral Ischaemia 12
Transient Ischemic Attacks 12
Ischemic Attack, Transient 44
Tia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:224
ICD10 33 G45.9
MeSH 44 D002546
NCIt 50 C50781
SNOMED-CT 68 38609002

Summaries for Transient Cerebral Ischemia

MedlinePlus : 43 A transient ischemic attack (TIA) is a stroke that lasts only a few minutes. It happens when the blood supply to part of the brain is briefly blocked. Symptoms of a TIA are like other stroke symptoms, but do not last as long. They happen suddenly, and include Numbness or weakness, especially on one side of the body Confusion or trouble speaking or understanding speech Trouble seeing in one or both eyes Difficulty walking Dizziness Loss of balance or coordination Most symptoms of a TIA disappear within an hour, although they may last for up to 24 hours. Because you cannot tell if these symptoms are from a TIA or a stroke, you should go to the hospital right away. TIAs are often a warning sign for future strokes. Taking medicine, such as blood thinners, may reduce your risk of a stroke. Your doctor might also recommend surgery. You can also help lower your risk by having a healthy lifestyle. This includes not smoking, not drinking too much, eating a healthy diet, and exercising. It is also important to control other health problems, such as high blood pressure and cholesterol. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Transient Cerebral Ischemia, also known as transient ischemic attack, is related to ischemia and stroke, ischemic, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Transient Cerebral Ischemia is NOTCH3 (Notch 3), and among its related pathways/superpathways are Immune response IL-23 signaling pathway and Neuroscience. The drugs Clopidogrel and Ticlopidine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and heart.

Disease Ontology : 12 A brain ischemia that is characterized by ischemia of brief duration and without resultant tissue death.

NINDS : 54 A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.

Wikipedia : 76 A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by loss of blood... more...

Related Diseases for Transient Cerebral Ischemia

Diseases related to Transient Cerebral Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 ischemia 31.4 CASP3 HSPA1A HSPA4 MAP2
2 stroke, ischemic 31.2 APOH CASP3 HSPA4 MAP2 NOTCH3
3 cytomegalovirus infection 29.8 CASP3 CCL2 IL1B
4 carotid artery occlusion 29.4 APOH HSPA1A MAP2
5 mini stroke 11.8
6 peripheral vascular disease 11.6
7 moyamoya disease 1 11.5
8 sneddon syndrome 11.4
9 moyamoya disease 2 11.4
10 moyamoya disease 6 with or without achalasia 11.4
11 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.2
12 buerger disease 11.2
13 telangiectasia, hereditary hemorrhagic, type 4 11.2
14 moyamoya disease 5 11.2
15 vertebrobasilar insufficiency 11.2
16 pulmonary arterio-veinous fistula 11.2
17 paresthesia 11.2
18 carotid artery disease 11.2
19 aganglionosis, total intestinal 11.1
20 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 11.0
21 arteries, anomalies of 10.4
22 diabetes mellitus 10.3
23 carotid stenosis 10.3
24 thrombosis 10.3
25 dementia 10.3
26 coronary artery anomaly 10.2
27 atrial fibrillation 10.2
28 fabry disease 10.1
29 purulent labyrinthitis 10.1 CCL2 IL1B
30 retinitis pigmentosa 73 10.1 CCL2 IL1B
31 alcohol abuse 10.1
32 glucose intolerance 10.1
33 herpes zoster 10.1
34 hyperglycemia 10.1
35 trypanosomiasis 10.0 CCL2 IL1B ODC1
36 neuropathy, hereditary sensory and autonomic, type vi 10.0 CASP3 LCN2
37 multiple sclerosis 10.0
38 rheumatoid arthritis 10.0
39 thrombophilia due to thrombin defect 10.0
40 takayasu arteritis 10.0
41 acute promyelocytic leukemia 10.0
42 deficiency anemia 10.0
43 arthritis 10.0
44 chronic kidney failure 10.0
45 hereditary hemorrhagic telangiectasia 10.0
46 leukemia 10.0
47 stuttering 10.0
48 iron deficiency anemia 10.0
49 atrial heart septal defect 10.0
50 iron metabolism disease 10.0

Comorbidity relations with Transient Cerebral Ischemia via Phenotypic Disease Network (PDN): (show top 50) (show all 89)


Active Peptic Ulcer Disease Acute Cystitis
Acute Myocardial Infarction Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Atrioventricular Block
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Failure
Chronic Maxillary Sinusitis Chronic Myocardial Ischemia
Communicating Hydrocephalus Conjunctivitis
Conversion Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Facial Paralysis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hyperlipoproteinemia, Type Iv
Hypertension, Essential Hypertensive Encephalopathy
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Inner Ear Disease
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Ischemic Heart Disease Kidney Disease
Labyrinthitis Left Bundle Branch Hemiblock

Graphical network of the top 20 diseases related to Transient Cerebral Ischemia:



Diseases related to Transient Cerebral Ischemia

Symptoms & Phenotypes for Transient Cerebral Ischemia

UMLS symptoms related to Transient Cerebral Ischemia:


seizures, tremor, angina pectoris, edema, back pain, amaurosis fugax, pain, chest pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, transient ischemic attacks, differing symptoms, transient ischemic attacks, stereotypic symptoms

Drugs & Therapeutics for Transient Cerebral Ischemia

Drugs for Transient Cerebral Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 431)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 113665-84-2, 120202-66-6 60606
2
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 55142-85-3 5472
3
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 50-78-2 2244
4
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
5
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
6
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
7
Candesartan cilexetil Approved Phase 4,Phase 3 145040-37-5 2540
8
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
9
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 137862-53-4 60846
10
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
11
Losartan Approved Phase 4 114798-26-4 3961
12
Acenocoumarol Approved, Investigational Phase 4,Phase 3 152-72-7 9052 54676537
13
Apixaban Approved Phase 4,Phase 3,Not Applicable 503612-47-3 10182969
14
Rivaroxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 366789-02-8
15
Amlodipine Approved Phase 4,Phase 3,Not Applicable 88150-42-9 2162
16
Phenprocoumon Approved, Investigational Phase 4,Phase 3 435-97-2 54680692 9908
17 tannic acid Approved Phase 4,Phase 3,Phase 2
18
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 94-09-7, 1994-09-7 2337
19
Amiodarone Approved, Investigational Phase 4,Phase 3,Not Applicable 1951-25-3 2157
20
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 6691 54678486
21
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
22
Dobutamine Approved Phase 4,Phase 3 34368-04-2 36811
23
Cilostazol Approved, Investigational Phase 4,Phase 3,Not Applicable 73963-72-1 2754
24
Enoxaparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6 772
25
Dalteparin Approved Phase 4,Phase 3,Phase 2 9005-49-6
26
Tranexamic Acid Approved Phase 4,Not Applicable 1197-18-8 5526
27
Febuxostat Approved Phase 4,Not Applicable 144060-53-7 134018
28
Ticagrelor Approved Phase 4,Phase 3,Phase 2 274693-27-5 9871419
29 Edoxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 480449-70-5
30
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
31
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
32
Dipyridamole Approved Phase 4,Phase 3,Not Applicable 58-32-2 3108
33
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
34
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
35
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
36
Metformin Approved Phase 4,Phase 3,Phase 2,Not Applicable 657-24-9 14219 4091
37
Sirolimus Approved, Investigational Phase 4,Phase 3,Not Applicable 53123-88-9 46835353 6436030 5284616
38
Everolimus Approved Phase 4,Not Applicable 159351-69-6 6442177
39
Miconazole Approved, Investigational, Vet_approved Phase 4,Not Applicable 22916-47-8 4189
40
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
41
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
42
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
43
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
44
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772 46507594
45
Simvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 79902-63-9 54454
46
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
47
Pravastatin Approved Phase 4,Phase 3,Not Applicable 81093-37-0 54687
48
Phytonadione Approved, Investigational Phase 4,Phase 3,Phase 2 84-80-0 4812 5284607
49
Adenosine Approved, Investigational Phase 4 58-61-7 60961
50
Allopurinol Approved Phase 4 315-30-0 2094

Interventional clinical trials:

(show top 50) (show all 717)
# Name Status NCT ID Phase Drugs
1 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
2 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
3 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
4 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
5 Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis Unknown status NCT02594800 Phase 4 Rosuvastatin
6 Treatment of Reperfusion Event by Vitamin C Infusion Unknown status NCT01090895 Phase 4 Vitamin C;Placebo
7 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC) Unknown status NCT02826200 Phase 4 Acenocoumarol
8 Preventive Effects of Ginseng Against Atherosclerosis Unknown status NCT02796664 Phase 4
9 Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
10 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4 Clopidogrel;Atorvastatin
11 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
12 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
13 The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion Unknown status NCT02594995 Phase 4 NBP
14 Hemocontrol's Effectiveness on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
15 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
16 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4 valsartan
17 Japanese Primary Prevention Project With Aspirin Unknown status NCT00225849 Phase 4 Aspirin
18 Hypertension Control Based on Home Blood Pressure Unknown status NCT00198562 Phase 4 Amlodipine, Losartan
19 Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF Unknown status NCT02256683 Phase 4 Dabigatran etexilate;Phenprocoumon
20 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
21 Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack Completed NCT00931788 Phase 4 Antihypertensive agents and lipid lowering therapy
22 Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke Completed NCT00147602 Phase 4 atorvastatin
23 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke Completed NCT00924638 Phase 4
24 Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI Completed NCT02640794 Phase 4 Clopidogrel;Aspirin
25 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
26 Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease Completed NCT00962988 Phase 4 Cost-Free Pharmacotherapy Group
27 Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial Completed NCT01559298 Phase 4 Aspirin (80 mg/d) + clopidogrel (75 mg/d);Aspirin
28 EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA Completed NCT00562588 Phase 4 Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg);ASA 100 mg qd
29 Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) Completed NCT02348723 Phase 4 Warfarin;Dabigatran Etexilate 150mg
30 Metformin-Dipyridamole Interaction Trial Completed NCT01613755 Phase 4 Metformin, dipyridamole;Metformin
31 Safety and Efficacy Study Comparing 3 New Types of Coronary Stents Completed NCT01166685 Phase 4
32 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery Completed NCT01334866 Phase 4
33 A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease Completed NCT00074984 Phase 4
34 NAVISTAR® THERMOCOOL® Catheter Post Approval Registry Completed NCT00964392 Phase 4
35 PreFER Managed Ventricular Pacing (MVP) For Elective Replacement Completed NCT00293241 Phase 4
36 The Effects of Levosimendan During Mitral Valve Surgery Completed NCT01969071 Phase 4 Levosimendan;Dobutamine
37 Platelet Inhibition and Transcranial Doppler (TCD)-Detected Microemboli During and After Carotid Artery Stenting (CAS) in Asymptomatic Patients Prior to Cardiac Surgery Completed NCT01146301 Phase 4 Clopidogrel
38 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) Completed NCT00234065 Phase 4 Cilostazol;Aspirin
39 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4 Valsartan;Non-ARB
40 Carvedilol Post-intervention Long-term Administration in Large-scale Trial Completed NCT01155635 Phase 4 Carvedilol;No Carvedilol
41 Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis Completed NCT00257283 Phase 4 Omega-3-acid ethyl esters 90
42 Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II) Completed NCT00289042 Phase 4 Enoxaparin
43 MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure Completed NCT00262119 Phase 4
44 OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed NCT00134160 Phase 4 Olmesartan medoxomil;Calcium channel blockers (amlodipine, azelnidipine)
45 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
46 Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial Completed NCT01035450 Phase 4
47 Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan Completed NCT01069302 Phase 4 Clopidogrel;Clopidogrel;Clopidogrel;Clopidogrel
48 Tranexamic Acid Dosing for Total Joint Arthroplasty Completed NCT02584725 Phase 4 Tranexamic Acid
49 Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™ Completed NCT00377611 Phase 4
50 Study of Heart and Renal Protection Completed NCT00125593 Phase 4 Simvastatin 20 mg;Ezetimibe 10mg;Placebo

Search NIH Clinical Center for Transient Cerebral Ischemia

Cochrane evidence based reviews: ischemic attack, transient

Genetic Tests for Transient Cerebral Ischemia

Anatomical Context for Transient Cerebral Ischemia

MalaCards organs/tissues related to Transient Cerebral Ischemia:

41
Brain, Eye, Heart, Spinal Cord, Retina, Endothelial, Kidney

Publications for Transient Cerebral Ischemia

Articles related to Transient Cerebral Ischemia:

(show top 50) (show all 1522)
# Title Authors Year
1
An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial. ( 30415083 )
2019
2
Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). ( 29084736 )
2018
3
Ischemic stroke/transient ischemic attack events and carotid artery disease in the absence of or with minimal coronary artery calcification: Results from the Multi-Ethnic Study of Atherosclerosis. ( 29852401 )
2018
4
A Modified Definition for Obstructive Sleep Apnea in Home Sleep Apnea Testing after Stroke or Transient Ischemic Attack. ( 29428326 )
2018
5
Long-Term Prognosis of Patients With Transient Ischemic Attack or Stroke and Symptomatic Vascular Disease in Multiple Arterial Beds. ( 29880551 )
2018
6
Genistein attenuates brain damage induced by transient cerebral ischemia through up-regulation of Nrf2 expression in ovariectomized rats. ( 29688134 )
2018
7
Effects of Scrambling trumpet Creeper flavone on transient cerebral ischemia model (TIA) in rats. ( 29686511 )
2018
8
Upregulation of heme oxygenase-1 protected against brain damage induced by transient cerebral ischemia-reperfusion injury in rats. ( 29805479 )
2018
9
Neuroprotection of ulinastatin on transient cerebral ischemia via antioxidative mechanisms. ( 29685007 )
2018
10
Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis. ( 29335335 )
2018
11
EAAC1 gene deletion reduces adult hippocampal neurogenesis after transient cerebral ischemia. ( 29720605 )
2018
12
Correction to: Inactivation of NSF ATPase Leads to Cathepsin B Release After Transient Cerebral Ischemia. ( 29796935 )
2018
13
Transient ischemic attack characterized by external strabismus of the left eye: A case report. ( 29901646 )
2018
14
TOPK Promotes Microglia/Macrophage Polarization towards M2 Phenotype via Inhibition of HDAC1 and HDAC2 Activity after Transient Cerebral Ischemia. ( 29896413 )
2018
15
Combined Treatment With Dichloroacetic Acid and Pyruvate Reduces Hippocampal Neuronal Death After Transient Cerebral Ischemia. ( 29593636 )
2018
16
Protective effects of D-Limonene against transient cerebral ischemia in stroke-prone spontaneously hypertensive rats. ( 29399074 )
2018
17
Tumor necrosis factor receptor 2 is required for ischemic preconditioning-mediated neuroprotection in the hippocampus following a subsequent longer transient cerebral ischemia. ( 29777731 )
2018
18
Treatment with Uric Acid Reduces Infarct and Improves Neurologic Function in Female Mice After Transient Cerebral Ischemia. ( 29398531 )
2018
19
Ulinastatin alleviates neurological deficiencies evoked by transient cerebral ischemia via improving autophagy, Nrf-2-ARE and apoptosis signals in hippocampus. ( 29750875 )
2018
20
Eagle syndrome: Transient ischemic attack and subsequent carotid dissection. ( 30481841 )
2018
21
Neuroprotective effects of a novel carnosine-hydrazide derivative on hippocampal CA1 damage after transient cerebral ischemia. ( 30522055 )
2018
22
A Selective Histamine H4 Receptor Antagonist, JNJ7777120, Is Protective in a Rat Model of Transient Cerebral Ischemia. ( 30420807 )
2018
23
Dissecting functional phenotypes of microglia and macrophages in the rat brain after transient cerebral ischemia. ( 30485549 )
2018
24
Xuebijing enhances neuroprotective effects of ulinastatin on transient cerebral ischemia via Nrf2-are signal pathways in the hippocampus. ( 30334406 )
2018
25
The Protective Effect of the Total Flavonoids of Abelmoschus esculentus L. Flowers on Transient Cerebral Ischemia-Reperfusion Injury Is due to Activation of the Nrf2-ARE Pathway. ( 30174782 )
2018
26
Letter by Chen et al Regarding Article, "Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis". ( 29622621 )
2018
27
Response by Ntaios et al to Letter Regarding Article, "Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis". ( 29622622 )
2018
28
Letter by Mojadidi et al Regarding Article, "Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis". ( 29643255 )
2018
29
Letter by Doshi et al Regarding Article, "Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis". ( 29643260 )
2018
30
Response by Ntaios et al to Letter Regarding Article, "Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis". ( 29643262 )
2018
31
Patent Foramen Ovale and Cryptogenic Stroke or Transient Ischemic Attack: To Close or Not to Close? A Systematic Review and Meta-Analysis. ( 29649819 )
2018
32
Subclavian Steal Syndrome as a Common Denominator of Both Acute Coronary Syndrome and Ipsilateral Transient Ischemic Attack. ( 30158373 )
2018
33
An Audit of Thrombophilia Testing in Patients with Ischemic Stroke or Transient Ischemic Attack: The Futility of Testing. ( 30143267 )
2018
34
Long-term treadmill exercise improves memory impairment through restoration of decreased synaptic adhesion molecule 1/2/3 induced by transient cerebral ischemia in the aged gerbil hippocampus. ( 29341891 )
2018
35
A case with CMTX1 disease showing transient ischemic-attack-like episodes. ( 29153916 )
2018
36
Predictors of CPAP adherence following stroke and transient ischemic attack. ( 30522873 )
2018
37
Electrical isolation of the left atrial appendage increases the risk of ischemic stroke and transient ischemic attack regardless of postisolation flow velocity. ( 30502771 )
2018
38
Self-perceived and Actual Risk of Further Stroke in Patients with Recurrent Stroke or Recurrent Transient Ischemic Attack in Thailand. ( 30503679 )
2018
39
Comparison of the Utility of Transesophageal Echocardiography in Patients With Acute Ischemic Stroke and Transient Ischemic Attack Stratified by Age Group (<60, 60 to 80, ≥80 Years). ( 30477726 )
2018
40
Prediabetes and Outcome of Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis. ( 30497898 )
2018
41
Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( 30511260 )
2018
42
Combining Diffusion-weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack. ( 30514189 )
2018
43
Occupational and leisure-time physical activity differentially predict 6-year incidence of stroke and transient ischemic attack in women. ( 30448859 )
2018
44
Early prediction of severity in acute ischemic stroke and transient ischemic attack using platelet parameters and neutrophil-to-lymphocyte ratio. ( 30411816 )
2018
45
Intensive Versus Moderate Statin Therapy Discontinuation in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. ( 30420288 )
2018
46
Oxidized Low-Density Lipoprotein to High-Density Lipoprotein Ratio Predicts Recurrent Stroke in Minor Stroke or Transient Ischemic Attack. ( 30355199 )
2018
47
Get With The Guidelines®-Stroke performance indicators in patients with transient ischemic attack. ( 30365623 )
2018
48
COMPASS-CP: An Electronic Application to Capture Patient-Reported Outcomes to Develop Actionable Stroke and Transient Ischemic Attack Care Plans. ( 30354371 )
2018
49
Long-Term Premorbid Blood Pressure and Cerebral Small Vessel Disease Burden on Imaging in Transient Ischemic Attack and Ischemic Stroke. ( 30354991 )
2018
50
Dual Antiplatelet Therapy for Minor Stroke and High-Risk Transient Ischemic Attack. ( 30355000 )
2018

Variations for Transient Cerebral Ischemia

ClinVar genetic disease variations for Transient Cerebral Ischemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 NOTCH3 NM_000435.2(NOTCH3): c.457C> T (p.Arg153Cys) single nucleotide variant Pathogenic rs797045014 GRCh38 Chromosome 19, 15192182: 15192182
2 NOTCH3 NM_000435.2(NOTCH3): c.457C> T (p.Arg153Cys) single nucleotide variant Pathogenic rs797045014 GRCh37 Chromosome 19, 15302993: 15302993
3 NOTCH3 NM_000435.2(NOTCH3): c.1450T> G (p.Cys484Gly) single nucleotide variant Likely pathogenic GRCh37 Chromosome 19, 15299088: 15299088
4 NOTCH3 NM_000435.2(NOTCH3): c.1450T> G (p.Cys484Gly) single nucleotide variant Likely pathogenic GRCh38 Chromosome 19, 15188277: 15188277

Expression for Transient Cerebral Ischemia

Search GEO for disease gene expression data for Transient Cerebral Ischemia.

Pathways for Transient Cerebral Ischemia

Pathways related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.36 BAD CCL2 IL1B PTK2B
2 12.35 GRIN2A MAP2 NOTCH3 SLC1A1
3
Show member pathways
11.96 CCL2 IL1B KMO KYNU
4
Show member pathways
11.92 CASP3 CCL2 MAP2 PTK2B
5
Show member pathways
11.89 CASP3 CCL2 IL1B LCN2
6 11.75 CASP3 CCL2 IL1B
7
Show member pathways
11.73 BAD CASP3 HSPA1A IL1B
8 11.71 CCL2 IL1B LCN2
9 11.67 CASP3 CCL2 IL1B
10 11.58 CASP3 CCL2 IL1B
11
Show member pathways
10.98 BAD CASP3 GRIN2A SLC1A1
12 10.87 CASP3 HSPA1A IL1B
13 10.64 CCL2 IL1B

GO Terms for Transient Cerebral Ischemia

Cellular components related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.44 BAD CASP3 GCKR HSPA1A HSPA4 IL1B
2 NMDA selective glutamate receptor complex GO:0017146 8.96 GRIN2A PTK2B

Biological processes related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.85 CCL2 GRIN2A IL1B PTK2B
2 response to estradiol GO:0032355 9.79 BAD CASP3 IL1B
3 cellular response to lipopolysaccharide GO:0071222 9.78 CCL2 IL1B KMO LCN2
4 cellular response to interleukin-1 GO:0071347 9.76 CCL2 KMO LCN2
5 memory GO:0007613 9.75 DRD1 GRIN2A IL1B
6 response to glucose GO:0009749 9.73 BAD CASP3 PTK2B
7 cellular response to organic cyclic compound GO:0071407 9.71 CASP3 CCL2 IL1B
8 response to glucocorticoid GO:0051384 9.7 BAD CASP3 IL1B
9 response to hydrogen peroxide GO:0042542 9.69 BAD CASP3 PTK2B
10 cytokine-mediated signaling pathway GO:0019221 9.65 BAD CASP3 CCL2 IL1B LCN2
11 chaperone-mediated protein complex assembly GO:0051131 9.63 HSPA1A HSPA4
12 long-term synaptic potentiation GO:0060291 9.63 DRD1 GRIN2A PTK2B
13 long-term synaptic depression GO:0060292 9.62 DRD1 PTK2B
14 dopamine metabolic process GO:0042417 9.61 DRD1 GRIN2A
15 activation of cysteine-type endopeptidase activity GO:0097202 9.61 BAD GRIN2A
16 NAD biosynthetic process GO:0009435 9.6 KMO KYNU
17 pyridine nucleotide biosynthetic process GO:0019363 9.59 KMO KYNU
18 cellular response to organic substance GO:0071310 9.58 CASP3 IL1B MAP2
19 tryptophan catabolic process GO:0006569 9.57 KMO KYNU
20 positive regulation of glucokinase activity GO:0033133 9.49 BAD GCKR
21 response to ethanol GO:0045471 9.46 BAD GRIN2A IL1B PTK2B
22 'de novo' NAD biosynthetic process from tryptophan GO:0034354 9.43 KMO KYNU
23 anthranilate metabolic process GO:0043420 9.37 KMO KYNU
24 quinolinate biosynthetic process GO:0019805 9.32 KMO KYNU
25 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.26 BAD CASP3 IL1B LCN2
26 response to drug GO:0042493 9.17 BAD CASP3 DRD1 GRIN2A IL1B LCN2

Molecular functions related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase activator activity involved in apoptotic process GO:0008656 8.96 BAD CASP3
2 NMDA glutamate receptor activity GO:0004972 8.62 GRIN2A PTK2B

Sources for Transient Cerebral Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....